Kawasaki Disease Diagnostic Criteria

ورودی‌های بالینی بیمار

حداقل ۱ — حداکثر ۳۰ • واحد: days

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
diagnosis
—category
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

Direct Clinical Answer

The Kawasaki Disease Diagnostic Criteria calculates calculating weight-based pediatric dosing and evaluating age-specific physiological parameters. Key inputs include fever duration. Scores guide titrating weight-adjusted medication dosing, monitoring developmental safety, and evaluating treatment response. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Diagnoses Kawasaki Disease using fever duration and principal clinical features. Kawasaki disease is a systemic vasculitis of childhood that can cause coronary artery aneurysms if untreated. Diagnosis requires fever ≥4 days plus ≥4 of 5 principal clinical features, or fever ≥5 days plus 2-3 features (incomplete Kawasaki).

Clinical Indication

The Kawasaki Disease Diagnostic Criteria is indicated for bedside clinical practice to support Diagnoses Kawasaki Disease using fever duration and principal clinical features. Kawasaki disease is a systemic vasculitis of childhood that can cause coronary artery aneurysms if untreated. Diagnosis requires fever ≥4 days plus ≥4 of 5 principal clinical features, or fever ≥5 days plus 2-3 features (incomplete Kawasaki).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Neonates, infants, children, and adolescents from birth up to 18 years of age. Clinical application is indicated across Pediatric emergency departments, pediatric inpatient wards, PICU, and pediatric primary care.

Limitations & Contraindications

Adult scoring thresholds and pharmacological formulas must never be applied to pediatric patients.

Clinical Pearls & Action Plan

Accurate weight-based dosing and age-stratified physiological vital sign reference ranges are foundational in pediatric clinical practice. Guideline pearl: Early diagnosis and treatment (within 10 days of fever onset) reduces risk of coronary artery abnormalities.

Formula & Variables:

Classic KD: Fever ≥4 days + ≥4 of 5 principal features. Incomplete KD: Fever ≥5 days + 2-3 principal features with supportive laboratory findings or coronary abnormalities

Input Parameters

NameTypeRequiredDescription
fever_durationintegerYesDuration of fever in days. Minimum 4 days required for diagnosis consideration(days)
bilateral_conjunctival_injectionstringYesBilateral conjunctival injection without exudate - Principal clinical feature
oral_changesstringYesOral changes including cracked and erythematous lips, strawberry tongue, or erythema of oral mucosa - Principal clinical feature
cervical_lymphadenopathystringYesCervical lymphadenopathy (≥1.5 cm diameter), usually unilateral - Principal clinical feature
extremity_changesstringYesExtremity changes including erythema of palms/soles, induration of hands/feet, or desquamation of fingertips - Principal clinical feature
polymorphous_rashstringYesPolymorphous rash (not vesicular or bullous) - Principal clinical feature

Evidence-Based References (EBM)

  • McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135(17):e927-e999.
  • Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-71.
  • Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47(2):232-4.
  • Yellen ES, Gauvreau K, Takahashi M, Burns JC, Shulman S, Baker AL, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics. 2010;125(2):e234-41.

Related calculators